Diana Fernandes de Rafael I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases. Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca Email Diana Fernandes de Rafael Email Instituciones de las que forman parte Investigador/a principal Bioquímica Clínica, Vehiculización de Fármacos y Terapia Vall Hebron Institut de Recerca I possess a Master in Pharmaceutical Sciences (2010) granted by the Faculty of Pharmacy from the Lisbon University, and a PhD degree in Pharmaceutical Technology (2017) from the same University. During my PhD I had the opportunity to do research stays at Ludwig Maximillian University (LMU), Munich, Bellvitge Biomedical Research Institute (IDIBELL) and Vall D'Hebron Research Institute (VHIR), Barcelona. Actually, I am a post-doctoral researcher at Drug Delivery and Targeting Group, VHIR working in the field of nanotechnology-based drug delivery systems applied to several diseases.
Being a multidisciplinary scientist, during 10 years of research career I acquired expertise in different areas of knowledge such as Pharmaceutical Technology, Nanomedicine, Chemistry, Molecular Biology, Cancer Signalling Pathways, Preclinical Validation, etc. My board knowledge in the field of biomedical sciences granted by my training as pharmacist and my research experience, allowed me to have a comprehensive and integrative view of the different stages of drug development from the bench to the bedside. My career has been fully dedicated to the design, development, and preclinical validation of innovative delivery systems for a wide range of challenging diseases with a special attention to oncology. My active participation at different international projects (12) and collaborations with a variety of research groups have resulted in the authorship of several publications in high impact peer-reviewed journals (35 publications, 15 as corresponding/first author, h-index 18). Also, she is co-inventor of two patents about delivery systems for gene delivery and the creation of cell penetrating peptides. Moreover, I am truly active in science dissemination both to share the knowhow with the pairs at international conferences, and also in citizenship dissemination actions. Additionally, due to her experience in the fields of Pharmaceutical Technology and Molecular Biology, I am giving classes at the Master of Molecular Biotechnology from the University of Barcelona. Most importantly, I was responsible for the supervision of the thesis of different pre-graduated, master and PhD students (14).
Proyectos NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales IP: NanoDIRE-CT - Uso de nanobodies para terapia dirigida contra células madre tumorales Colaboradores: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Simon Schwartz Navarro Entidad financiadora: Ministerio de Ciencia e Innovación-MICINN Financiación: 322172.61 Referencia: RTC2019-006809-1 Duración: 01/09/2020 - 31/12/2023 BIODEGRADABLE NANOPARTICLES OF SIMVASTATIN AS NEW THERAPEUTIC TOOL FOR CHRONIC LIVER DISEASE (NANOSIM) IP: Joan Genescà Ferrer Colaboradores: Maria Nieves Martell Pérez-Alcalde, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 199946.45 Referencia: AC18/00033 Duración: 01/01/2019 - 31/12/2022 Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH IP: María José Buzón Gómez Colaboradores: Desenvolupament de noves nanopartícules funcionals dirigides al nòdul limfàtic per a l'eliminació del reservori latent de VIH, Félix Pumarola Segura, Juan Lorente Guerrero, Laura García Latorre, Jordi Temprana Salvador, Joaquin Seras Franzoso, Marc Pellicer Sarasa, Simon Schwartz Navarro, Jordi Navarro Mercadé, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Judit Grau Exposito, Meritxell Genesca Ferrer, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Entidad financiadora: Fundació La Marató de TV3 Financiación: 199998.75 Referencia: 20180510 Duración: 10/05/2019 - 31/12/2022 Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. IP: Mejora del tratamiento de las enfermedades de depósito lisosomal mediante vehículos nanométricos optimizados. Colaboradores: Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael Entidad financiadora: Instituto de Salud Carlos III Financiación: 116160 Referencia: PI18/00871 Duración: 01/01/2019 - 30/06/2022 Paginación Primera página « Página anterior ‹ Página 1 Página 2 Página actual 3 Página 4 Siguiente página › Última página »
